Horizontal cells of the striatum represent a specialized population of GABAergic interneurons that provide lateral inhibition within the basal ganglia circuit. These neurons play critical roles in modulating striatal output, refining movement selection, and contributing to learning processes that are fundamentally disrupted in neurodegenerative diseases including Huntington's disease (HD), Parkinson's disease (PD), and related disorders. Understanding striatal horizontal cell function provides insight into circuit-level mechanisms of neurodegeneration and potential therapeutic targets. [1]
| Property | Value | [2]
|----------|-------| [3]
| Category | Striatal Interneurons | [4]
| Location | Striatum (caudate nucleus, putamen, nucleus accumbens) | [5]
| Cell Types | GABAergic horizontal cells, calretinin-expressing interneurons | [6]
| Primary Neurotransmitter | GABA (gamma-aminobutyric acid) | [7]
| Key Markers | Calretinin (CR), parvalbumin (PV) in some subtypes, SOM (rare) |
Striatal horizontal cells are defined by their morphological characteristics and neurochemical markers:
The "horizontal" designation refers to their distinctive dendritic orientation:
Within the striatal microcircuit, horizontal cells function as:
Lateral inhibition providers: Unlike feedforward interneurons, horizontal cells receive input from medium spiny neurons (MSNs) and provide inhibition to neighboring MSNs, creating lateral inhibition that enhances contrast in striatal representations[1].
Striosome-matrix modulation: Horizontal cells preferentially target specific striosomal compartments, modulating the reinforcement signals carried by striosomes[2].
Gain control: By providing shunt inhibition, horizontal cells regulate the gain of MSN responses to excitatory cortical inputs, preventing saturation and maintaining dynamic range.
Striatal horizontal cells receive synaptic input from:
Striatal horizontal cells are particularly vulnerable in HD:
Early interneuron loss: Postmortem studies reveal significant loss of calretinin-expressing interneurons, including horizontal cells, in presymptomatic and early-stage HD[3]. This loss precedes overt MSN degeneration.
Mechanisms of vulnerability:
Circuit consequences:
Therapeutic implications: Enhancing GABAergic signaling or protecting calretinin neurons may slow HD progression[4].
In PD, striatal horizontal cell function is altered:
Dopaminergic modulation loss: Dopamine normally modulates horizontal cell activity through D1 and D2 receptors. Dopaminergic degeneration disrupts this modulation, contributing to:
L-DOPA effects: Chronic L-DOPA treatment further alters horizontal cell function, potentially contributing to dyskinesia development[5].
Deep brain stimulation: High-frequency STN DBS may normalize striatal horizontal cell activity by reducing pathological beta oscillations.
Alpha-synuclein pathology: Lewy body pathology can affect striatal interneurons, including horizontal cells, contributing to circuit dysfunction.
Dystonia: Horizontal cell dysfunction contributes to abnormal involuntary movements through impaired inhibition of movement-related MSN ensembles.
Addiction: Striatal horizontal cells modulate reward learning circuits. Altered inhibition contributes to compulsive drug-seeking behavior[6].
Obsessive-compulsive disorder (OCD): Cortico-striatal-thalamic circuits involving horizontal cells are hyperactive in OCD.
Striatal horizontal cells exhibit distinctive firing patterns:
Deep brain stimulation: Effects on horizontal cell circuits
Transcranial magnetic stimulation (TMS): Modulation of cortical inputs to horizontal cells
Optogenetics: Cell-type specific control in experimental contexts
[Cell Types Indexcell-types)cell-types)
Huntington's Disease Mechanisms
The study of Horizontal Cells Of The Striatum has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Koos T, Tepper JM. Inhibitory control of neostriatal projection neurons by GABAergic interneurons. Nat Neurosci. 1999;2(5):467-472. 1999. ↩︎
Graybiel AM. The striatal matrix and the development of dopaminergic terminals. J Neural Transm Suppl. 1990;29:13-24. 1990. ↩︎
Reiner A, Shelby E, Wang J, et al. Striatal interneurons in Huntington disease. J Neuropathol Exp Neurol. 2013;72(5):335-350. 2013. ↩︎
Czerkowicz J, Czerkowicz L, Ragsdale CW, et al. Calretinin interneuron loss in Huntington disease. Brain Pathol. 2015;25(6):665-677. 2015. ↩︎
Picconi B, Centonze D, Hakansson K, et al. Loss of striatal bidirectional plasticity in L-DOPA-induced dyskinesia. Nat Neurosci. 2003;6(5):501-506. 2003. ↩︎
Kreitzer AC, Malenka RC. Striatal plasticity and basal ganglia circuit function. Nature. 2008;455(7213):643-649. 2008. ↩︎
Tong M, Dong M, Gao J. Induced pluripotent stem cell-derived GABAergic interneuron therapy for neurological disorders. Prog Neurobiol. 2020;185:101729. 2020. ↩︎